Literature DB >> 2416057

Sequence of the immunodominant epitope for the surface protein on sporozoites of Plasmodium vivax.

T F McCutchan, A A Lal, V F de la Cruz, L H Miller, W L Maloy, Y Charoenvit, R L Beaudoin, P Guerry, R Wistar, S L Hoffman.   

Abstract

Plasmodium vivax is one of the four malaria parasites that cause disease in humans. The structure of the immunodominant repeating peptide of the circumsporozoite (CS) protein of P. vivax was determined. A fragment of P. vivax DNA that encodes this tandemly repeating epitope was isolated by use of an oligonucleotide probe whose sequence is thought to be conserved in CS protein genes. DNA sequence analysis of the P. vivax clone indicates that the CS repeat is nine amino acids in length (Gly-Asp-Arg-Ala-Asp-Gly-Gln-Pro-Ala). The structure of the repeating region was confirmed with synthetic peptides and monoclonal antibodies directed against P. vivax sporozoites. This information should allow synthesis of a vaccine for P. vivax that is similar to the one being tested for P. falciparum.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2416057     DOI: 10.1126/science.2416057

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  19 in total

1.  Isolation and serological characterization of a Plasmodium vivax recombinant antigen.

Authors:  Y D Sharma; V P Sharma; P Ray; S Laal; S D Sawant; S Verma
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

2.  An immunodominant site of gamma-zein1 is in the region of tandem hexapeptide repeats.

Authors:  A Esen
Journal:  J Protein Chem       Date:  1990-08

3.  The genome of Plasmodium cynomolgi is partitioned into separable domains which appear to differ in sequence stability.

Authors:  T F McCutchan; J B Dame; R W Gwadz; K D Vernick
Journal:  Nucleic Acids Res       Date:  1988-05-25       Impact factor: 16.971

4.  Cell adhesion to a motif shared by the malaria circumsporozoite protein and thrombospondin is mediated by its glycosaminoglycan-binding region and not by CSVTCG.

Authors:  S M Gantt; P Clavijo; X Bai; J D Esko; P Sinnis
Journal:  J Biol Chem       Date:  1997-08-01       Impact factor: 5.157

5.  Demonstration of antigenic polymorphism in Plasmodium vivax malaria with a panel of 30 monoclonal antibodies.

Authors:  P V Udagama; P H David; J S Peiris; Y G Ariyaratne; K L Perera; K N Mendis
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

6.  A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.

Authors:  Anjali Yadava; Jetsumon Sattabongkot; Michael A Washington; Lisa A Ware; Victoria Majam; Hong Zheng; Sanjai Kumar; Christian F Ockenhouse
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

7.  Monoclonal antibodies to the circumsporozoite protein repeats of a Plasmodium vivax-like human malaria parasite and Plasmodium simiovale.

Authors:  V Udhayakumar; S H Qari; P Patterson; W E Collins; A A Lal
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

8.  Detection of vivax malaria sporozoites naturally infected in Anopheline mosquitoes from endemic areas of northern parts of Gyeonggi-do (Province) in Korea.

Authors:  Hyeong Woo Lee; E-Hyun Shin; Shin Hyeong Cho; Hee Il Lee; Chung Lim Kim; Wook Gyo Lee; Sung Ung Moon; Jong Soo Lee; Won Ja Lee; Tong-Soo Kim
Journal:  Korean J Parasitol       Date:  2002-06       Impact factor: 1.341

9.  Antibody response of humans to the circumsporozoite protein of Plasmodium vivax.

Authors:  E D Franke; C M Lucas; E San Roman
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

10.  Immunogenicity of a non-repetitive sequence of Plasmodium falciparum circumsporozoite protein in man and mice.

Authors:  G Del Giudice; Q Cheng; D Mazier; N Berbiguier; J A Cooper; H D Engers; C Chizzolini; A S Verdini; F Bonelli; A Pessi
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.